表紙
市場調査レポート

後天性 (自己免疫性) 溶血性貧血:パイプライン分析

Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 200919
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
後天性 (自己免疫性) 溶血性貧血:パイプライン分析 Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015
出版日: 2015年09月09日 ページ情報: 英文 60 Pages
概要

自己免疫性溶血性貧血(AIHA)とは、外因性要因 (免疫不全、医薬品、感染症、赤血球の物理的損傷、毒素への曝露など) によって引き起こされた溶血性貧血のことを指します。主な症状には、黄疸やめまい、発熱、頭痛、貧血、悪寒などが挙げられます。また、主な疾病素質には年齢や性別、家族歴などがあります。

当レポートでは、世界各国での後天性 (自己免疫性) 溶血性貧血治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

後天性 (自己免疫性) 溶血性貧血の概要

治療薬の開発

  • 後天性 (自己免疫性) 溶血性貧血向けパイプライン製品:概要
  • 後天性 (自己免疫性) 溶血性貧血向けパイプライン製品:比較分析

各企業で開発中の後天性 (自己免疫性) 溶血性貧血治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

後天性 (自己免疫性) 溶血性貧血治療薬:開発中の製品の一覧 (企業別)

後天性 (自己免疫性) 溶血性貧血治療薬の開発に従事している企業

  • Agios Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Hansa Medical AB
  • Shire Plc

後天性 (自己免疫性) 溶血性貧血:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • AG-348
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • C1エステラーゼ阻害剤 (人体用)
  • エクリズマブ
  • Endoglycosidase of Streptococcus pyogenes
  • 化膿連鎖球菌由来のエンドグリコシダーゼ
  • TNT-003
  • TNT-009

後天性 (自己免疫性) 溶血性貧血治療薬:パイプライン製品の最新動向

後天性 (自己免疫性) 溶血性貧血治療薬:休止中のプロジェクト

後天性 (自己免疫性) 溶血性貧血の関連製品の開発マイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7151IDB

Summary

Global Markets Direct's, 'Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2015', provides an overview of the Acquired (Autoimmune) Hemolytic Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acquired (Autoimmune) Hemolytic Anemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acquired (Autoimmune) Hemolytic Anemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acquired (Autoimmune) Hemolytic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acquired (Autoimmune) Hemolytic Anemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acquired (Autoimmune) Hemolytic Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Acquired (Autoimmune) Hemolytic Anemia Overview
  • Therapeutics Development
    • Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Overview
    • Pipeline Products for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis
  • Acquired (Autoimmune) Hemolytic Anemia - Therapeutics under Development by Companies
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Acquired (Autoimmune) Hemolytic Anemia - Products under Development by Companies
  • Acquired (Autoimmune) Hemolytic Anemia - Companies Involved in Therapeutics Development
    • Agios Pharmaceuticals, Inc.
    • Alexion Pharmaceuticals, Inc.
    • Hansa Medical AB
    • Shire Plc
  • Acquired (Autoimmune) Hemolytic Anemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AG-348 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Endoglycosidase of Streptococcus pyogenes - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TNT-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TNT-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acquired (Autoimmune) Hemolytic Anemia - Recent Pipeline Updates
  • Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects
  • Acquired (Autoimmune) Hemolytic Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 12, 2015: Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase Deficiency
      • May 21, 2015: Agios to Present Clinical and Preclinical Data On AG-348 at the 20th Congress of the European Hematology Association
      • Mar 24, 2015: Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency
      • Dec 08, 2014: Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency
      • Nov 06, 2014: Agios Pharmaceuticals To Present Phase 1 Data On AG-348 At The 2014 American Society Of Hematology Annual Meeting
      • Oct 06, 2014: Agios Pharmaceuticals to Provides Update on AG-348 Webcast R&D Day on October 15, 2014
      • Jun 09, 2014: Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK Deficiency, a Rare, Hemolytic Anemia
      • Apr 17, 2014: Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency
      • Apr 14, 2014: True North Therapeutics Publishes Study in Blood Demonstrating Ex Vivo Efficacy of a C1s Antibody in Cold Agglutinin Disease Patient Samples
      • Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2015
  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Hansa Medical AB, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Pipeline by Shire Plc, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia Therapeutics - Recent Pipeline Updates, H2 2015
  • Acquired (Autoimmune) Hemolytic Anemia - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia, H2 2015
  • Number of Products under Development for Acquired (Autoimmune) Hemolytic Anemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top